Intellia Therapeutics, Inc.
A clinical-stage biotechnology company in Cambridge, Massachusetts, that uses CRISPR gene-editing technology to develop medicines for genetic diseases. Founded in 2014 with Nobel Prize-winning scientist Jennifer Doudna as a co-founder, it made history in 2021 by delivering the first-ever CRISPR edit inside a human body, targeting a protein that causes a rare heart condition. Its name blends "intelligence" with a biotech-style suffix.
Granted 480.2K · Sold 191.0K
Granted 24.9K · Bought 150.0K
Granted 174.8K · Sold 13.8K
Granted 118.5K · Sold 27.4K
Granted 24.9K · Bought 100.0K
Granted 76.8K · Sold 8.5K
Granted 98.2K · Sold 27.3K
Granted 70.6K · Sold 25.4K
Granted 45.0K · Sold 16.8K
Granted 49.1K · Sold 10.7K
Granted 31.7K · Sold 5.4K
Granted 29.4K · Sold 10.4K
Granted 24.9K
Granted 24.9K · Sold 795
Granted 24.9K · Sold 1.5K
Granted 24.9K · Sold 3.1K
Granted 32.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Leonard John MPresident and CEO, Director · 15 transactions | +31.6% | 1.21M | 480.2K | — | 191.0K |
| Cohen Fred EDirector · 4 transactions | +419.4% | 216.7K | 24.9K | 150.0K | — |
| Dulac Edward J IIIEVP, Chief Financial Officer · 5 transactions | — | 161.0K | 174.8K | — | 13.8K |
| Basta JamesEVP, General Counsel · 9 transactions | +183.6% | 156.8K | 118.5K | — | 27.4K |
| Chase William JDirector · 4 transactions | +659.1% | 143.9K | 24.9K | 100.0K | — |
| Schultes Birgit CEVP, Chief Scientific Officer · 4 transactions | — | 137.7K | 76.8K | — | 8.5K |
| Lebwohl DavidEVP, Chief Medical Officer · 8 transactions | +132.8% | 131.2K | 98.2K | — | 27.3K |
| Clark ElianaEVP, Chief Technical Officer · 13 transactions | +107.9% | 93.9K | 70.6K | — | 25.4K |
| Sepp-Lorenzino LauraEVP, Chief Scientific Officer · 7 transactions | +62.7% | 77.4Kas of Jan 2025 | 45.0K | — | 16.8K |
| Dube Michael PVP, Chief Accounting Officer · 8 transactions | — | 69.5K | 49.1K | — | 10.7K |
| Goddard GlennEVP, Chief Financial Officer · 3 transactions | +61.4% | 69.2Kas of Mar 2024 | 31.7K | — | 5.4K |
| Hicks DerekEVP, Chief Business Officer · 3 transactions | +46.5% | 59.9Kas of Jan 2025 | 29.4K | — | 10.4K |
| Keresty GeorgiaDirector · 3 transactions | +154.4% | 41.1K | 24.9K | — | — |
| Bhanji MunaDirector · 6 transactions | +196.9% | 36.4K | 24.9K | — | 795 |
| Verwiel FrankDirector · 4 transactions | +200% | 35.1K | 24.9K | — | 1.5K |
| Goodman JesseDirector · 5 transactions | +186.4% | 33.6K | 24.9K | — | 3.1K |
| Goff BrianDirector · 3 transactions | — | 32.6K | 32.6K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -92.1K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.